Manish A. Shah, MD, discusses the 5-year outcomes from the phase 3 KEYNOTE-590 study of first-line pembrolizumab plus chemotherapy in patients with advanced esophageal cancer.
An international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker.
A new targeted treatment shows promise for select patients with stomach cancer sciencedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencedaily.com Daily Mail and Mail on Sunday newspapers.